Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, Nikolaishvili-Feinberg N, Midkiff BR, Liu J, Zhang W, Yang C, Wang X, Frye SV, Earp HS, Shields JM, Graham DK. Schlegel J, et al. Among authors: shields jm. J Clin Invest. 2013 May;123(5):2257-67. doi: 10.1172/JCI67816. Epub 2013 Apr 15. J Clin Invest. 2013. PMID: 23585477 Free PMC article.
Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.
Sambade MJ, Camp JT, Kimple RJ, Sartor CI, Shields JM. Sambade MJ, et al. Among authors: shields jm. Radiother Oncol. 2009 Dec;93(3):639-44. doi: 10.1016/j.radonc.2009.09.006. Epub 2009 Oct 23. Radiother Oncol. 2009. PMID: 19853943 Free PMC article.
A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines.
Carson C, Omolo B, Chu H, Zhou Y, Sambade MJ, Peters EC, Tompkins P, Simpson DA, Thomas NE, Fan C, Sarasin A, Dessen P, Shields JM, Ibrahim JG, Kaufmann WK. Carson C, et al. Among authors: shields jm. Pigment Cell Melanoma Res. 2012 Jul;25(4):514-26. doi: 10.1111/j.1755-148X.2012.01010.x. Epub 2012 Jun 1. Pigment Cell Melanoma Res. 2012. PMID: 22540896 Free PMC article.
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.
Jeck WR, Parker J, Carson CC, Shields JM, Sambade MJ, Peters EC, Burd CE, Thomas NE, Chiang DY, Liu W, Eberhard DA, Ollila D, Grilley-Olson J, Moschos S, Neil Hayes D, Sharpless NE. Jeck WR, et al. Among authors: shields jm. Pigment Cell Melanoma Res. 2014 Jul;27(4):653-63. doi: 10.1111/pcmr.12238. Epub 2014 Apr 7. Pigment Cell Melanoma Res. 2014. PMID: 24628946 Free PMC article. Clinical Trial.
Mechanisms of chromosomal instability in melanoma.
Kaufmann WK, Carson CC, Omolo B, Filgo AJ, Sambade MJ, Simpson DA, Shields JM, Ibrahim JG, Thomas NE. Kaufmann WK, et al. Among authors: shields jm. Environ Mol Mutagen. 2014 Jul;55(6):457-71. doi: 10.1002/em.21859. Epub 2014 Feb 24. Environ Mol Mutagen. 2014. PMID: 24616037 Free PMC article.
CD200 is induced by ERK and is a potential therapeutic target in melanoma.
Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, Buehler C, Kim WY, Shields JM, Penland S, Bear JE, Thomas NE, Serody JS, Sharpless NE. Petermann KB, et al. Among authors: shields jm. J Clin Invest. 2007 Dec;117(12):3922-9. doi: 10.1172/JCI32163. J Clin Invest. 2007. PMID: 18008004 Free PMC article.
Development of DNA damage response signaling biomarkers using automated, quantitative image analysis.
Nikolaishvilli-Feinberg N, Cohen SM, Midkiff B, Zhou Y, Olorvida M, Ibrahim JG, Omolo B, Shields JM, Thomas NE, Groben PA, Kaufmann WK, Miller CR. Nikolaishvilli-Feinberg N, et al. Among authors: shields jm. J Histochem Cytochem. 2014 Mar;62(3):185-96. doi: 10.1369/0022155413516469. Epub 2013 Dec 5. J Histochem Cytochem. 2014. PMID: 24309508 Free PMC article.
78 results